SinoMab BioScience Ltd (hkse:03681) Share Price

Company Profile

Business description
SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren’s syndrome (SS) as well as non-Hodgkin’s lymphoma (NHL), and other indications. The group derives revenue from Hong Kong.
Contact
No. 15 Science Park West Avenue
Units 303 and 305 to 307
Hong Kong Science Park, Pak Shek Kok
New Territories
Hong Kong
HKG
T: +852 34269833
https://www.sinomab.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
36

Recommended

IFM lobs reasonable takeover offer.

Adrian Atkins | 28 April 2026

Microsoft, Amazon, Alphabet, and Meta will all release quarterly earnings. Here’s what analysts are looking for.

Jillian Moore | 28 April 2026

Corning’s optical fiber business is thriving, and the Meta deal derisks its supply buildout, but success isn’t guaranteed.

Ananya Chag | 27 April 2026

Index	Last price	Change	% Change
All Ordinaries	8,915.70	16.00	0.18%
CAC 40	8,044.09	60.00	-0.74%
DAX 40	23,958.42	59.84	-0.25%
Dow JONES (US)	49,141.93	25.86	-0.05%
FTSE 100	10,258.16	74.63	-0.72%
HKSE	26,111.84	432.06	1.68%
NASDAQ	24,663.80	223.30	-0.90%
Nikkei 225	59,917.46	619.90	-1.02%
NZX 50 Index	12,770.30	5.90	0.05%
S&P 500	7,138.80	35.11	-0.49%
S&P/ASX 200	8,687.00	9.40	0.11%
SSE Composite Index	4,107.51	28.88	0.71%